ClinicalTrials.gg
Sign In
TerminatedNCT04210414Cleave-blastUpdated Jun 15, 2022

Cleave-stage Transfer on Day 3 Versus Day 5 Transfer When Only One Embryo Available

An interventional study of Embryo transfer in Infertility, sponsored by Ibn Sina Hospital. Terminated at 3 sites in Egypt. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2022-06-15.

Sponsored by Ibn Sina Hospital · Not applicable, Interventional, and Other

Why this study was terminated
COVID19 Pandemic affected recruitment across 2020 and the stringent inclusion criteria makes the proposed sample size to be likely unachievable in reasonable period.
Phase
Not applicable
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
Female
01

Study summary

When only one embryo is available after in vitro fertilization, the option is to transfer either day 3 or day 5. There is no randomized trial compared the day 3 to day 5 for this subgroup.

Read the detailed description

Recruitment is very slow. The TSC will discuss termination next meeting with the DMC.

02

Conditions studied

  • Infertility

Browse trials for

03

In context

Infertility

2,085 studies on the registry are indexed under Infertility; 357 are open to participants now.

This study's enrollment of 83 is below the median of 135 across 1,412 interventional studies indexed under Infertility.

Browse Infertility studies →

Lead sponsor

Ibn Sina Hospital is the lead sponsor of 28 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infertile couple with only one embryo available for transfer

Exclusion criteria

Exclusion Criteria:

  • ineligible for study
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Day 3 transfer

    Transfer on day 3 when only one embryo is available

    Other: Embryo transfer

  • Experimental
    Day 5 transfer

    Transfer on day 5 when only one embryo is available

    Other: Embryo transfer

Interventions

  • OtherEmbryo transfer

    Transfer of only one embryo

06

What researchers measure

Primary outcomes

  1. Ongoing pregnancy rate

    Time frame: within 20 weeks of gestation

Secondary outcomes

  1. Biochemical pregnancy rate

    Time frame: One month

  2. clinical pregnancy

    Time frame: 7 weeks of gestation

  3. Embryo development after In vitro fertilization cycle

    Time frame: 6 days after in vitro fertilization

07

Study locations

3 sites
  • Banon Assiut
    Assiut, Egypt
  • Qena Fertility Center
    Qena, 123456, Egypt
  • IbnSina IVF Center, IbnSina Hospital
    Sohag, 12345, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Nov 2021, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2019
First posted
Dec 24, 2019
StartActual
Jan 10, 2020
Primary completionActual
Nov 10, 2021
CompletionActual
Nov 10, 2021
Last update
Jun 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04210414
Lead sponsor
Ibn Sina Hospital
Responsible party
Muhammad Fawzy (IVF Lab Director, Ibn Sina Hospital) — Principal investigator
First posted
Dec 24, 2019
Start date
Jan 10, 2020
Primary completion
Nov 10, 2021
Completion
Nov 10, 2021
Last update
Jun 15, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Infertility →

Other studies from this sponsor

Ibn Sina Hospital

Start the discussion